RBT-0813

N/A

Report date: 2024/11/15 11:25:21

Base Information

Drug NameRBT-0813
Drug Alias NameRBT0813TB-49304
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein modulators
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTwist Bioscience HQ
China Registration ClassN/A

Develop Information

Active CompaniesTwist Bioscience HQRevelar Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A